Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

829
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
829
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
Cancer Vaccines01:30

Cancer Vaccines

861
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
861
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting the timing of first sustained cognitive worsening in Alzheimer's disease using real-world clinical data and machine learning.

medRxiv : the preprint server for health sciences·2026
Same author

Posterior Reversible Encephalopathy Syndrome in a Patient with Multiple System Atrophy and Multiple Myeloma.

Movement disorders clinical practice·2026
Same author

Proposed mechanisms of neuroprotection for nicotine in Parkinson's disease.

Journal of Parkinson's disease·2025
Same author

Sleep spindle variation in patients with Parkinson's disease on first nights of sub-optimal deep brain stimulation.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2024
Same author

Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson's disease.

bioRxiv : the preprint server for biology·2024
Same author

The case of an 85-year-old woman with subacute onset of bilateral chorea.

Annals of clinical and translational neurology·2024
Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026
Same journal

Editorial introduction.

Current opinion in neurology·2026
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
See all related articles

Related Experiment Video

Updated: Dec 15, 2025

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
05:39

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

3.6K

Immunotherapy in progressive supranuclear palsy.

Pavan A Vaswani1, Abby L Olsen

  • 1Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Current Opinion in Neurology
|July 14, 2020
PubMed
Summary
This summary is machine-generated.

Tau immunotherapy shows promise for progressive supranuclear palsy (PSP). While early trials demonstrate safety, further research is needed to confirm the efficacy of these treatments for this neurodegenerative disease.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.8K

Related Experiment Videos

Last Updated: Dec 15, 2025

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination
05:39

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

3.6K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.8K

Area of Science:

  • Neurodegenerative diseases
  • Immunotherapy
  • Tauopathies

Background:

  • Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by the aggregation of abnormal tau protein.
  • Extracellular tau fragments are increasingly implicated in PSP progression.
  • Extracellular tau presents a target for immunotherapy.

Purpose of the Study:

  • To review the current landscape of tau immunotherapy for PSP.
  • To assess the safety and efficacy of emerging immunotherapies.
  • To explore alternative therapeutic strategies like stem cell therapy.

Main Methods:

  • Review of clinical trial data for tau-targeting monoclonal antibodies.
  • Analysis of safety and futility outcomes from Phase 1 and 2 trials.
  • Inclusion of emerging therapies such as stem cell therapy and plasma infusion.

Main Results:

  • Three monoclonal antibodies (ABBV-8E12, BIIB092, UCB0107) targeting extracellular tau are in clinical development.
  • Phase 1 trials for ABBV-8E12 and BIIB092 showed safety, but Phase 2 studies failed futility analyses.
  • UCB0107 reported Phase 1 safety, with a Phase 2 study planned. Stem cell and plasma therapies are also under investigation.

Conclusions:

  • Extracellular tau is a viable target for PSP immunotherapy due to its role in disease progression.
  • Current tau immunotherapies have demonstrated safety but have yet to prove efficacy in clinical trials.
  • Further clinical investigation is required to establish effective immunotherapeutic strategies for PSP.